免疫调节药物联合地塞米松治疗伴单克隆免疫球蛋白沉积的增生性肾小球肾炎的疗效
该回顾性研究分析了64例伴单克隆免疫球蛋白沉积的增生性肾小球肾炎(PGNMID)患者,比较免疫调节药物(IMiD)组、激素组和硼替佐米联合地塞米松/利妥昔单抗(BD/RTX)组的预后。结果显示IMiD组和BD/RTX组的肾脏缓解率及完全缓解率均显著高于激素组,但严重不良事件在IMiD和BD/RTX组更常见。作者认为IMiD联合地塞米松对PGNMID患者实现肾脏缓解有效。
要点
- IMiD组和BD/RTX组末次随访时肾脏缓解率及完全缓解率均显著高于激素组。
- 高血压和高血清肌酐(>1.24 mg/dl)降低肾脏缓解,低C3水平、IMiD和BD/RTX治疗与肾脏缓解正相关。
- 肾组织IgG3和高血清肌酐是肾脏不良预后指标;严重不良事件在IMiD和BD/RTX组更常见。
核心结论
- 作者认为IMiD联合地塞米松对PGNMID患者实现肾脏缓解有效。
研究设计与样本
- 回顾性分析2010年1月1日至2020年12月31日南京国家肾脏疾病临床医学研究中心64例PGNMID患者的临床病理数据,分为激素组、IMiD组和BD/RTX组。
主要发现
- IMiD组28例、激素组26例、BD/RTX组10例;激素组血清M蛋白检出率显著低于其他两组。
- 末次随访时IMiD组和BD/RTX组的肾脏缓解率均显著高于激素组(分别P=0.001和P=0.03),肾脏完全缓解率亦均显著高于激素组(分别P=0.001和P=0.01)。
- 多因素logistic分析显示高血压和高血清肌酐(>1.24 mg/dl)降低肾脏缓解,低C3水平、IMiD和BD/RTX治疗与肾脏缓解正相关。
- 多因素Cox分析显示肾组织IgG3和高血清肌酐为肾脏不良预后指标。
- 严重不良事件在IMiD组和BD/RTX组较激素组更常见(分别P=0.072和P=0.035)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunomodulatory drugs (IMiDs) plus dexamethasone are effective for plasma cell dyscrasias, but the treatment efficacy of IMiD in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) has been rarely reported. METHODS: We retrospectively analyzed the clinicopathologic data of 64 patients with PGNMID (steroid, IMiD, and bortezomib and dexamethasone/Rituximab [BD/RTX] groups) from January 1, 2010 to December 31, 2020, at the National Clinical Research Center of Kidney Disease in Nanjing. The prognosis of patients receiving different treatment regimens were compared. Factors potentially affecting renal prognosis and renal response were evaluated. RESULTS: Twenty-eight, 26 and 10 PGNMID patients were divided into IMiD group, steroid group and BD/RTX group respectively. The rate of serum M protein detection was significantly lower in the steroid group than in the other 2 groups. Renal remission (P = 0.001 and P = 0.03, respectively) rates and renal complete remission (CR) (P = 0.001 and P = 0.01, respectively) rates were significantly higher in the IMiD and BD/RTX groups than in the steroid group at the last follow-up. Multivariate logistic analysis identified that hypertension and high serum creatinine (SCr) levels (>1.24 mg/dl) decreased renal remission, whereas low C3 levels, IMiD and BD/RTX treatments were positively associated with renal remission. Multivariate Cox analysis identified IgG3 in renal tissue and high SCr levels as poor renal prognostic indicators. Severe adverse events were more common in the IMiD and BD/RTX groups than in the steroid group (P = 0.072 and P = 0.035, respectively). CONCLUSION: Our results suggest that IMiDs plus dexamethasone is effective for achieving renal remission in PGNMID patients.
引用
- Zhou H, Li M, Zeng C, et al. Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits. Kidney Int Rep. 2022. PMID: 36217516. doi:10.1016/j.ekir.2022.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。